Dogwood Therapeutics, INC 8-K filings

Virios Therapeutics reported its first quarter 2024 financial results, provided a corporate update, and announced that top-line results from a Long-COVID phase 2 study are expected in the second half of 2024.

Virios Therapeutics has received a second delisting notice from Nasdaq for failing to maintain a minimum share price of $1.00 and has requested a hearing to present a plan for regaining compliance.

Virios Therapeutics stockholders approved a reverse stock split and a proposal to adjourn the special meeting if necessary to solicit additional proxies.

Virios Therapeutics announced its fourth quarter and full year 2023 financial results, along with updates on its clinical programs for Long-COVID and fibromyalgia.

Virios Therapeutics announces a 10% salary reduction for all employees and a 10% reduction in cash compensation for non-employee directors, accompanied by stock option grants, effective March 1, 2024.